Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07206290) titled 'Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: University Medical Center Groningen
Condition:
Chronic Kidney Disease
Intervention:
Drug: Survodutide (BI 456906)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 2, 2026
Target Sample Size: 120
To know more, visit https://clinicaltrials.gov/study/NCT07206290
Published by HT Digital Content ...